Edwards Lifesciences (EW) Gets Favorable FDA Panel Vote for SAPIEN via Transfemoral, Transapical Delivery

Edwards Lifesciences Corporation (NYSE: EW), reports that a U.S. Food and Drug Administration (FDA) Advisory Panel voted in favor of recommending approval of the Edwards SAPIEN transcatheter heart valve via transfemoral and transapical delivery for the treatment of high-risk patients with severe, symptomatic aortic stenosis. The panel voted 11 to 0, with one abstention, that the benefits of the heart valve outweighed the risks for these patients.

Edwards submitted a Premarket Application (PMA) in April 2011 based on data from the high-risk cohort (Cohort A) of The PARTNER Trial. Cohort A compared the outcomes of patients at high risk for traditional open-heart surgery evenly randomized to receive either surgical aortic valve replacement or the Edwards SAPIEN valve via transfemoral or transapical delivery. In November 2011, the FDA approved SAPIEN via transfemoral delivery for the treatment of inoperable patients with severe, symptomatic aortic stenosis.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Apollo Global Management (APO) to Buy US Silica (SLCA) for $15.50/sh Cash
• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• VinFast Auto (VFS) Appoints Tham Chee Soon to its Board, Ngan Wan Sing Winston Resigns